

ORAL COMMUNICATIONS - TUESDAY, 16TH OF MAY – (15:00-16:30) - ROOM D

SESSION 3 | Molecular and Cell biology

Chairman: Carmen Thomas

Co-chairman: Dan Zilberstein

C0441	CHARACTERISATION OF AN UNUSUAL LEISHMANIA HSP70 FAMILY MEMBER, HRP4 <i>Sima Drini; Gerald F Späth; Najma Rachidi;</i>
C0515	THE ESSENTIAL VALOSIN-CONTAINING PROTEIN P97/VCP/CDC48 PLAYS A CENTRAL ROLE IN LEISHMANIA AMASTIGOTE SURVIVAL <i>Bruno Guedes Aguiar; Prasad Kottayil Padmanabhan; Ouafa Zghidi-Abouzid; Carole Dumas; Barbara Papadopoulou;</i>
C0630	METABOLOMICS ANALYSIS OF LEISHMANIA PROMASTIGOTES TREATED WITH THE 6-AMINONICOTINAMIDE <i>Shawgi H. Almugadam; Kevin Rattigan; Fiona Achcar; Carlo Contini; Martina Maritati; Gianluca Rugna; Franco Dallochio; Tiziana Bellini; Stefania Hanau; Michael Barrett;</i>
C0796	FUNCTIONAL GENOMICS OF LEISHMANIA INFECTION AND IDENTIFICATION OF NOVEL VIRULENT FACTORS <i>Vyacheslav Yurchenko; Aygul Ishemgulova Yurchenko; Natalya Kraeva Yurchenko; Anzhelika Butenko Yurchenko; Jan Votýpka; Tereza Leštinová; Jana Hlavacova; Petr Volf;</i>
C0821	DELETION OF THE A2 VIRULENCE FACTOR THROUGH CRISPR-CAS9 TARGETING RESULTS IN ATTENUATED LEISHMANIA DONOVANI, ROLE OF A2 AS A CHAPERONE PROTEIN <i>Vyacheslav Yurchenko; Aygul Ishemgulova Yurchenko; Natalya Kraeva Yurchenko; Anzhelika Butenko Yurchenko; Jan Votýpka; Tereza Leštinová; Jana Hlavacova; Petr Volf;</i>
C1002	CHROMOSOMAL SEGREGATION IN THE PROTOZOAN PARASITE LEISHMANIA: THE QUEST FOR CENTROMERES <i>Garcia Silva Maria Rosa; Sollelis Lauriane; McPherson Cameron Ross; Crobu Lucien; Stanojic Slavica; Bastien Patrick; Scherf Artur; Pagès Michel Michel; Sterkers Yvon;</i>
C1324	LEISHMANIA IFT140 MUTANTS LACK FLAGELLA, ARE RELATIVELY NORMAL AS PROMASTIGOTES, BUT ARE UNABLE TO SURVIVE AS AMASTIGOTES <i>Tiffanie Fowlkes; Stephen Beverley;</i>
C1461	THE LEISHMANIA MRNA-BOUND PROTEOME CHANGES THROUGHOUT THE LIFE CYCLE; CANDIDATE TRANS-REGULATORS OF PARASITE DIFFERENTIATION <i>Luis M. De Pablos; Adam A. Dowle; Pegine Walrad;</i>
C1839	CHARACTERIZATION OF LEISHMANIA DONOVANI EXPERIMENTAL HYBRIDS DERIVED FROM PHLEBOTOMUS ORIENTALIS AND P. ARGENTIPES <i>David Santos-Mateus; Jovana Sádlová; Jitka Myskova; Veronika Seblova; Asrat Hailu; Michael Miles; Matthew Yeo; Petr Volf;</i>

SESSION 4 | Mucocutaneous leishmaniasis, diffuse cutaneous leishmaniasis, post-kala-azar leishmaniasis

Chairman: Poonam Salotra

Co-chairman: Jorge Arévalo

C0484	INTRACELLULAR TRAFFICKING OF GFP EXPRESSING LEISHMANIA AETHIOPICA IN TERMINALLY DIFFERENTIATED THP-1 CELLS <i>Medhavi Ranatunga; Giulia Getti; Paul Dyer; Simon Richardson;</i>
C0658	POST-KALA-AZAR DERMAL LEISHMANIASIS WITHOUT PREVIOUS HISTORY OF VISCERAL LEISHMANIASIS: A CASE SERIES ON IDENTIFICATION, CONFIRMATION, AND TREATMENT <i>Md Hasnain Golam; Mohammad Shomik Sohel; Prakash Ghosh; Mamun Rashid Or; Md Hossain Shakhawat; Shinjiro Hamano; Dinesh Mondal;</i>
C1676	REASONS FOR SCREEN FAILURES IN CLINICAL TRIALS CARRIED OUT IN THE LEISHMANIASIS EAST AFRICA PLATFORM TRIAL SITES <i>Lilian Were Oketch; Dr. Jane Mbui; Prof Joseph Olobo; Prof Asrat Hailu; Prof Ahmed Musa; Prof Eltahir Khalil; Raymond Omollo; Alexandra Solomos Solomos; Thadeous Egondi Egondi; Truphosa Omollo; Robert Kimutai; Jorge Alvar; Monique Wasunna; Fabiana Alves;</i>
C1891	POST-KALA-AZAR DERMAL LEISHMANIASIS (PKDL) TREATED WITH AMBULATORY SHORT COURSE AMBISOME <i>Koert Ritmeijer; Sakib Burza; Asish Kumar Das; Raman Mahajan; Pradeep Das; Ahmed Be-Nazir; Margriet den Boer;</i>

ROOM C - 15:30-17:00

SESSION 5 - Drug development: conventional and alternative. Clinical and experimental therapy in cutaneous and visceral leishmaniasis

Chairman: Séverine Blesson

Co-chairman: Sakib Burza

C0640	MODELING MILTEFOSINE EXPOSURE AFTER ALLOMETRIC DOSING IN PEDIATRIC VISCERAL LEISHMANIASIS PATIENTS IN KENYA AND UGANDA <i>A.E. Kip; A. Solomos; F. Alves; L. Were; R. Kimutai; J.H.M. Schellens; J.H. Beijnen; M. Wasunna; R. Juma; J. Mbui; J. Olobo; T.P.C. Dorlo;</i>
C0976	THE ASSOCIATION OF MILTEFOSINE AND PENTOXIFYLLINE TO TREAT MUCOSAL LEISHMANIASIS: A PILOT CLINICAL TRIAL IN BRAZIL <i>Sofia Sales Martins; Ciro Martins Gomes; Raimunda Raimunda Nonata Ribeiro Sampaio;</i>
C1245	THERMOTHERAPY ALONE OR COMBINED WITH A SHORT-COURSE SYSTEMIC TREATMENT AS AN ALTERNATIVE THERAPY IN PERUVIAN CUTANEOUS LEISHMANIASIS: A CASE SERIES <i>Braulio Mark Valencia Arroyo; Laura Mori-Llontop; Ana Quispe; Andrea K Boggild; Alejandro Llanos-Cuentas; Byron Arana;</i>
C1265	ORAL PENTOXIFYLLINE ASSOCIATED WITH PENTAVALENT ANTIMONY: A RANDOMIZED TRIAL FOR CUTANEOUS LEISHMANIASIS <i>Paulo Roberto Lima Machado; Graça Brito ; Mayra Dourado; Luiz Henrique Guimarães; Albert Schriefer; Edgar Marcelino de Carvalho;</i>
C1476	IDENTIFICATION OF SNPS ASSOCIATED WITH THE THERAPEUTIC RESPONSE IN PATIENTS WITH CUTANEOUS LEISHMANIASIS <i>Mariana del Socorro Rosales Chilama; Julieth Murillo; Alvaro Martinez; Adriana Navas; Deninson Alejandro Vargas; Maria Claudia Barrera; Andres Castillo; María Adelaida Gómez;</i>
C1552	PHASE II RANDOMIZED CLINICAL TRIAL OF THE EFFICACY AND SAFETY OF AMBISOME[®] IN COMBINATION WITH SODIUM STIBOGLUCONATE OR MILTEFOSINE VERSUS MILTEFOSINE MONOTHERAPY FOR AFRICAN VISCERAL LEISHMANIASIS <i>Monique Wasunna; Simon Njenga; Manica Balasegaram; Neal Alexander; Raymond Omollo; Tansy Edwards; Thomas Dorlo; Brima Musa; Mohammed Hassan Sharaf Ali; Mohamed Yassein; George Kirigi; Rashid Juma; Anke E. Kip; Gerard Schoone; Asrat Hailu; Joseph Olobo; Sally Ellis; Robert Kimutai; Susan Wells; Eltahir Awad Gasim Khalil; Nathalie Strub- Wourgaft; Fabiana Alves; Ahmed Musa;</i>
C1584	SAFETY OF AVAILABLE TREATMENTS FOR VISCERAL LEISHMANIASIS IN BRAZIL: RESULTS FROM THE LV BRASIL TRIAL <i>Joelle Rode; Dorcas Lamounier Costa; Carlos Henrique Nery Costa; Roque Pacheco de Almeida; Enaldo Viera de Melo; Sílvio Fernando Guimarães de Carvalho; Ana Rabello; Andréa Lucchesi de Carvalho; Anastácio de Queiroz Sousa; Robério Dias Leite; Simone Soares Lima; Thais Alves Amaral; Fabiana Piovesan Alves; Gustavo Adolfo Sierra Romero;</i>

C1625	PILOT STUDY OF SAFETY/EFFICACY OF TOPICAL LIPOSOMAL AMPHOTERICIN B FOR THE TREATMENT OF CUTANEOUS LEISHMANIASIS CAUSED BY L. MAJOR <i>Ali Khamesipour Khamesipour; Akram Miramin Mohammadi; Alireza Firooz; Mansour Nassiri Kashani; Seyed Ebrahim Eskandari; Mahmood Reza Jaafari; Amir Javadi; Yahya Dowlati;</i>
C1588	COHORT OBSERVATIONAL STUDY TO ESTIMATE THE PROPORTION OF POST KALA-AZAR DERMAL LEISHMANIASIS (PKDL) WITH AT LEAST TWO YEARS FOLLOW UP AFTER TREATMENT WITH THREE NEW TREATMENT REGIMENS IN VL ENDEMIC DISTRICTS OF BIHAR <i>Vishal Goyal; Vidya Nand Rabi Das; Krishna Pandey; Fabiana Alves; Suman Rijal; Pradeep Das; Jorge Alvar;</i>